title: Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/class-1 obese adults.
abstract: The objective of this study (clinicaltrials.gov NCT01858376) was to determine the effect of oral supplementation of a standardized extract of Phyllanthus emblica (CAPROS(®)) on cardiovascular disease (CVD) risk factors in overweight adult human subjects from the US population. Overweight/Class-1 obese (body-mass index: 25-35) adult subjects received 500 mg of CAPROS supplement b.i.d for 12 weeks. The study design included two baseline visits followed by 12 weeks of supplementation and then 2 weeks of washout. At all visits, peripheral venous blood was collected in sodium citrate tubes. Lipid profile measurements demonstrated a significant decrease in calculated low-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein following 12 weeks of CAPROS supplementation when compared to averaged baseline visits. Circulatory high-sensitivity C reactive protein (hs-CRP) levels were significantly decreased after 12 weeks of supplementation. In addition, both ADP- and collagen-induced platelet aggregation was significantly downregulated following 12 weeks of supplementation. Overall, the study suggests that oral CAPROS supplementation may provide beneficial effects in overweight/Class-1 obese adults by lowering multiple global CVD risk factors.
authors.affiliation: Department of Surgery, The Ohio State University Wexner Medical Center , Columbus, Ohio, USA .
authors.forename: Savita
authors.initials: S
authors.lastname: Khanna
authors.forename: Amitava
authors.initials: A
authors.lastname: Das
authors.forename: James
authors.initials: J
authors.lastname: Spieldenner
authors.forename: Cameron
authors.initials: C
authors.lastname: Rink
authors.forename: Sashwati
authors.initials: S
authors.lastname: Roy
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019587:Dietary Supplements / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications*; D050177:Overweight / Q000097:blood / Q000150:complications*; D029842:Phyllanthus emblica / Q000737:chemistry*; D010936:Plant Extracts / Q000008:administration & dosage*; D010974:Platelet Aggregation / Q000187:drug effects*; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D010936:Plant Extracts; D002097:C-Reactive Protein
keywords: Phyllanthus emblica; cardiovascular disease; high-sensitivity C-reactive protein; platelet aggregation